Epstein Secrets

17 M Jun-13 Series E $117M $1.00 36.2% IRR $6.88 DACART CAPITAL LIC EFTA_R1_01138846 EFTA02295572 Advisory Board Thomas Shenk, Ph.D. Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from

ITAL LLC EFTA_R1_01138807 EFTA02295533 The Case for Investment • Investment opportunities identified • First 4 investments are teed up • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees - 2%/20% DAC..., CAPITAL Li_c EFTA_R1_01138808 EFTA02295534

es B Series E $17M $117M 4) cr 1 .UU nn 36.2% IRR 4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from

AR I C API JAL LLC7 • r EFTA00506112 The Case for Investment ■ Investment opportunities identified ■ First 4 investments are teed up • Short time & limited capital to profit/liquidity ■ Managing Director's hands-on involvement • Competitive fees - 2%/20% DACARTGAPIIAL LLC, EFTA00506113 The Case for Invest

t >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from

nt. DACAR1 LLC: EFTA00506161 The Case for Investment • Investment opportunities identified • First 5 investments are ready, 3 backups • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees — 2%/20% DACART CAPIIAL LLCL EFTA00506162 The Case for Invest